Research programme: selective androgen receptor antagonists - Biogen Idec

Drug Profile

Research programme: selective androgen receptor antagonists - Biogen Idec

Alternative Names: CNF 316

Latest Information Update: 24 Feb 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biogen Idec
  • Class
  • Mechanism of Action Heat-shock protein inhibitors; Testosterone congener inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Prostate cancer

Most Recent Events

  • 03 May 2006 Conforma Therapeutics has been acquired and merged into Biogen Idec
  • 19 Dec 2001 Preclinical development for Prostate cancer in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top